^
Association details:
| Biomarker: | TMPRSS2-ERG fusion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xofigo (radium Ra-223 dichloride) (Alpha radiation emitter) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer
Excerpt:
...Changes in MAF of clonal SNV`Change in clonal mutation MAF and change in pain`Change in clonal mutation MAF and change in tumor markers`Change in clonal mutation MAF and markers of bone metabolism`Change in clonal mutation MAF and presence of the TMPRSS2-ERG fusion gene...
Source:
Title:
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
Published date:
06/02/2022
Excerpt:
This is a retrospective study of mCRPC patients who received Ra-223 and genetic testing within the Mayo Clinic database (Arizona, Florida, and Minnesota) and Tulane Cancer Center....Patients with a TMPRSS2-ERG mutation exhibited a trend toward lower OS 15.4 months (95% confidence interval [CI] 10.0-NR) versus 26.8 months (95% CI 20.9-35.1). Patients with an RB deletion had a lower PFS 6.0 months (95% CI 1.28-NR) versus 9.0 months (95% CI 7.3-11.1) and a lower OS 13.9 months (95% CI 5.2-NR) versus 26.5 months (95% CI 19.8-33.8).
DOI:
10.1002/pros.24375
